Short answer
Neuronetics, Inc. (STIM) filed an 8-K current report with the SEC on August 11, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). August 11, 2026 press release announces Neuronetics’ financial results for Q2 and first six months ended June 30, 2026.
Neuronetics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- August 11, 2026 press release announces Neuronetics’ financial results for Q2 and first six months ended June 30, 2026
- Investors should review the accompanying exhibit for revenue, profitability, cash flow and outlook details
Item 7.01 · Regulation FD Disclosure
- Investor presentation released August 11, 2026, covering Neuronetics’ outlook and upcoming fiscal 2026 expectations
- Presentation addresses revenue, expenses and growth, making it relevant to valuation and earnings expectations
- Key execution risks include profitability, cash flow, credit facility terms and ability to continue as a going concern
- Business exposure remains concentrated in NeuroStar system sales, reimbursement, physician demand and competing therapies
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $41.6M, up 9.1%, driven by Greenbrook revenue $26.9M, up 16.8%
- NeuroStar revenue declined 2.7% to $14.7M, highlighting continued pressure in the core device business
- Adjusted EBITDA reached $0.3M versus a $5.6M loss, supported by gross-margin expansion to 51.1% and 12% lower operating expenses
- Net loss narrowed to $3.4M, or $0.05 per share, versus $10.1M, or $0.15, while shares outstanding increased
- Cash totaled $25M at June 30 versus $34.1M at December 31; FY2026 guidance targets revenue $160M-$164M and operating cash flow/investing of negative $10.5M-$14.5M
Item EX-99.2 · Exhibit EX-99.2
- August 2026 presentation raises FY2026 revenue guidance to $160M-$164M, representing 7%-10% YoY growth
- FY2026 gross margin guidance of 48%-50%, with operating expenses of $91M-$96M excluding approximately $4M stock compensation
- Cash flow from operations and investing projected at $(10.5)M to $(14.5)M, signaling continued cash burn despite improved profitability
- Q2 2026 revenue $41.6M, up 9% YoY, while gross margin reached 51% versus 47% and adjusted EBITDA improved to $254,000 from $(5.6)M
- Greenbrook integration expands the platform to 92 clinics and 800+ NeuroStar sites, adding Spravato capabilities and potential psychedelic-treatment infrastructure
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Neuronetics, Inc. 8-K filings
Get the next STIM 8-K as it lands
Follow STIM for push alerts, or ask the research agent what this filing means.